Dipeptidyl peptidase-4 (DPP-4) inhibitors

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

Daily linagliptin is effective and reduces hypoglycemia risk relative to multidose insulin in type 2 diabetes patients with mild-to-moderate hyperglycemia who are undergoing non-cardiac surgery, suggest the results of a randomized controlled study.

Continuation of sitagliptin during initiation of insulin glargine therapy results in a greater reduction in glycated hemoglobin, without increased hypoglycemia, than discontinuation in patients with type 2 diabetes, study data show.

Findings from the CARMELINA trial suggest that the dipeptidyl peptidase-4 inhibitor linagliptin has a similar cardiovascular safety profile to placebo when added to standard care in high-risk type 2 diabetes patients.

The results of a network meta-analysis offer strong support for use of sodium-glucose cotransporter 2 inhibitors to prevent heart failure (HF) in patients with type 2 diabetes.

Dapagliflozin plus saxagliptin offers a realistic alternative to both insulin and glimepiride in patients with type 2 diabetes poorly controlled by metformin, show two studies presented at the ADA’s 78th Scientific Sessions in Orlando, Florida, USA.

A network meta-analysis published in JAMA offers indirect comparisons of the survival benefits associated with use of the most recent antidiabetic agents.

Adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin and sulfonylurea treatment may improve glycemic control in patients with type 2 diabetes and high cardiovascular risk, a post-hoc analysis of the EXAMINE trial suggests.

Researchers have detected a possible increased risk for inflammatory bowel disease among users of dipeptidyl peptidase-4 inhibitors.

An analysis of electronic health records reveals changes in prescribing patterns for type 2 diabetes treatments in the UK over the past decade.

Results of a US database study suggest that the sodium-glucose co-transporter-2 inhibitor canagliflozin is associated with a lower risk for heart failure hospitalization compared with three other classes of antidiabetes agent.

Analysis of the SAVOR-TIMI trial supports a relationship between low blood pressure and cardiovascular risk in patients with type 2 diabetes.

Metformin status at the time of initial dipeptidyl peptidase 4 inhibitor use may influence the effect these agents have on cardiovascular outcomes, be it positive or negative, suggest results of a hypothesis-generating meta-analysis.

Results of the VIVIDD trial indicate that it is unclear whether treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin has a beneficial effect on cardiac outcomes among patients with heart failure and type 2 diabetes.

The CVD-REAL investigators have presented further results demonstrating the effects of sodium-glucose co-transporter 2 inhibitors on cardiovascular outcomes in real-world clinical practice.

One of the first original research sessions of EASD 2017 included updates from the TECOS, SUSTAIN 6, and DURATION-7 and -8 trials.

Patients with type 2 diabetes receiving treatment with sodium-glucose co-transporter-2 inhibitors have a lower risk for adverse cardiovascular outcomes than those using other glucose-lowering drugs, results from the CVD-REAL Nordic study suggest.

Linagliptin significantly improves glycemic control in individuals with type 2 diabetes and early-stage kidney disease, but fails to significantly ameliorate glomerular damage, show findings from the MARLINA-T2D trial.

One of the final sessions on Saturday featured the presentation of new, and mostly positive, data on medications for glycemic control in patients with type 2 diabetes.

Research findings indicate that patients with type 2 diabetes may have an increased risk for diabetic ketoacidosis when they begin treatment with a sodium–glucose cotransporter 2 inhibitor.